AARD Stock Analysis: Buy, Sell, or Hold?
AARD - Aardvark Therapeutics, Inc. Common Stock
$3.90
0.26 (7.14%)
▲
5d:
+5.98%
30d:
-40.82%
90d:
-23.38%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When AARD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AARD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AARD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AARD is currently trading at $3.90, which is considered slightly low relative to its 30-day fair value range of $3.58 to $5.42.
Technical Outlook: Technically, AARD is in a strong downtrend. Immediate support is located at $3.40, while resistance sits at $4.12. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: AARD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.44 (+296.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AARD is in a strong downtrend. Immediate support is located at $3.40, while resistance sits at $4.12. The stock is showing strong short-term momentum, up 7.1% recently.
Market Sentiment: AARD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.44 (+296.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.58 -
$5.42
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.1%)
- BULLISH: Trading 296.0% below Wall St target ($15.44)
Trading Range Analysis
30-Day Trading Range
$3.58 -
$5.42
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.62
(16.0%)
Support & Resistance Levels
Support Level
$3.40
Resistance Level
$4.12
Current Trend
Strong Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.20
Wall Street Target
$15.44
(+296.0%)
Share & Embed Analysis
Last updated: June 15, 2026 7:53 AM ET
Data refreshes hourly during market hours. Next update: 8:53 AM
Data refreshes hourly during market hours. Next update: 8:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AARD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 66 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 62 BUY |
